Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens.
Hematopoietic stem cell transplantation (HSCT) for autoimmune diseases have been, because of safety reasons, overwhelmingly autologous. Results are, in general, encouraging with improvement in quality of life, a remission of up to several years, and perhaps in some diseases improved survival. This indicates that further study of autologous HSCT especially under phase III design is warranted. However, the ultimate goal of HSCT is cure of otherwise incurable autoimmune diseases. For this reason, allogeneic HSCT in carefully selected high-risk patients with autoimmune diseases using strategies to minimize both regimen-related toxicity and graft-versus-host disease (GVHD) is ongoing at Northwestern University and will be reviewed briefly.
Oyama
Y
Y
Division of Immunotherapy, Northwestern University Medical School, 320 E. Superior, 3-489, Chicago, IL 60611, USA.
Traynor
A E
AE
Barr
W
W
Burt
R K
RK
D001172:Arthritis, Rheumatoid / Q000628:therapy; D001327:Autoimmune Diseases / Q000628:therapy*; D002986:Clinical Trials as Topic; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D018579:Patient Selection; D012595:Scleroderma, Systemic / Q000628:therapy; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome